Table 1.
Baseline characteristics and prior treatments
| Elranatamab SC monotherapy (n = 55) | |
|---|---|
| Median age, years | 64.0 (42–80) |
| Sex | |
| Female | 26 (47.3) |
| Male | 29 (52.7) |
| Race | |
| White | 37 (67.3) |
| Black/African American | 11 (20.0) |
| Asian | 4 (7.3) |
| Not reported | 3 (5.5) |
| ECOG PS | |
| 0–1 | 50 (90.9) |
| ≥2 | 5 (9.1) |
| R-ISS stage at initial diagnosis | |
| Stage I | 14 (25.5) |
| Stage II | 20 (36.4) |
| Stage III | 11 (20.0) |
| Not reported | 10 (18.2) |
| Cytogenetic risk | |
| Higha | 16 (29.1) |
| Standard | 35 (63.6) |
| Unknown | 4 (7.3) |
| Extramedullary disease | 17 (30.9) |
| Median number of prior anti-myeloma therapies | 5.0 (2–14) |
| Triple-class refractoryb | 50 (90.9) |
| Refractory to last line of therapy | 49 (89.1) |
| Prior PIs | 55 (100.0) |
| Bortezomib | 52 (94.5) |
| Carfilzomib | 47 (85.5) |
| Ixazomib | 18 (32.7) |
| Prior ImiDs | 55 (100.0) |
| Lenalidomide | 54 (98.2) |
| Pomalidomide | 52 (94.5) |
| Thalidomide | 9 (16.4) |
| CC-92480 | 2 (3.6) |
| Iberdomide | 1 (1.8) |
| Prior anti-CD38 therapy | 54 (98.2) |
| Daratumumab | 52 (94.5) |
| Isatuximab | 4 (7.3) |
| Otherc | 1 (1.8) |
| Prior BCMA-targeted therapy | 13 (23.6) |
| Anti-BCMA ADC | 4 (7.3) |
| CAR-T | 5 (9.1) |
| Both anti-BCMA ADC and CAR-T | 4 (7.3) |
Values are median (range) or n (%). Data cutoff was 30 September 2022. Patients may have received more than one treatment within a given therapy class.
aDefinition of high cytogenetic risk includes t(4;14), t(14;16) and del(17p).
bTriple-class refractory disease is refractory to at least one PI, one ImiD and one anti-CD38 therapy.
cOne patient treated at 360 μg kg−1 received prior anti-myeloma therapy with a CD38×CD3 bispecific molecule.
ImiD, immunomodulatory drug; PI, proteasome inhibitor; R-ISS, Revised International Staging System; SC, subcutaneous.